Cargando…
Adjuvant treatment of early-stage melanoma by local i.d. administration of low-dose CpG-B and GM-CSF increases recurrence-free survival: long-term follow-up of three randomized clinical trials
Autores principales: | de Gruijl, Tanja D, Koster, Bas D, van den Hout, Mari FCM, Sluijter, Berbel JR, Molenkamp, Barbara G, Vuylsteke, Ronald JCLM, van Leeuwen, Paul AM, Scheper, Rik J, van den Tol, Petrousjka, van den Eertwegh, Alfons |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649384/ http://dx.doi.org/10.1186/2051-1426-3-S2-P201 |
Ejemplares similares
-
Pre-operative intradermal administration of CpG-B ± GM-CSF in stage I-III melanoma patients arms the sentinel lymph node: evidence for reduced tumor spread
por: van den Hout, Mari F, et al.
Publicado: (2013) -
Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node
por: van den Hout, Mari F. C. M., et al.
Publicado: (2016) -
In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma
por: Koster, Bas D., et al.
Publicado: (2019) -
T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A(+)CD141(+) cDC1 and CD14(+) antigen-presenting cell recruitment
por: Koster, Bas D, et al.
Publicado: (2021) -
Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial
por: Koster, Bas D., et al.
Publicado: (2019)